Texas Transplant Institute

San Antonio, Texas 98109

8 studies enrolling now · 70 studies all time

What they study most

AML, AML, Adult, Acute Graft-versus-host Disease, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Adenovirus, Adult B Cell ALL, Advanced Fibrosis

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — Recruiting now
• Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — Recruiting now
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL — Recruiting now
• DALY II USA/ MB-CART2019.1 for DLBCL — Recruiting now
• Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma — Recruiting now
• Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases — Recruiting now
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
• A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) — Completed
• Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) — Completed
• Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) — Completed
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — Running, not enrolling
• Expanded Access Program for OOS Obe-cel — Available (expanded access)
• Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) — Running, not enrolling
• A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) — Stopped early
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease — Completed
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) — Stopped early
• Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma — Stopped early
• Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704) — Completed
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk — Completed
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia — Stopped early
• FT538 in Subjects With Advanced Hematologic Malignancies — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease — Completed
• A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants — Completed
• Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies — Status unconfirmed
• Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies — Completed
• Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) — Completed
• Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) — Completed
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) — Stopped early
• Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) — Completed
• Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) — Completed
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) — Completed
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) — Completed
• Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202) — Completed
• Allogeneic Transplant in HIV Patients (BMT CTN 0903) — Completed
• A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) — Completed
• Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD — Completed
• Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) — Completed
• Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) — Completed
• Double Cord Versus Haploidentical (BMT CTN 1101) — Completed
• Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) — Completed
• Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) — Completed
• Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) — Completed
• Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) — Completed
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) — Completed
• Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients — Completed
• Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) — Completed
• Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL — Stopped early